Evidence map›Paper›PMID 39950103›Full record

ReviewFrontiers in oncology2024

Unraveling the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma: the "omics" era.

Alberto Barchi, Giuseppe Dell'Anna, Luca Massimino, Francesco Vito Mandarino, Edoardo Vespa, Edi Viale, Sandro Passaretti, Vito Annese, Alberto Malesci, Silvio Danese and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. The Role of Mucins in Esophageal Inflammatory Diseases.Journal of personalized medicine · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Emerging Biomarkers for Managing Barrett's Esophagus.Gastrointestinal endoscopy clinics of North America · 2026
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alberto BarchiGastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy.
Giuseppe Dell'AnnaGastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy.
Luca MassiminoGastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy.
Francesco Vito MandarinoGastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy.
Edoardo VespaGastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy.
Edi VialeGastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy.
Sandro PassarettiGastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy.
Vito AnneseGastroenterology and Gastrointestinal Endoscopy Unit, IRCCS Policlinico San Donato, Milan, Italy.
Alberto MalesciGastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy.
Silvio DaneseGastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy.
Federica UngaroGastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Barrett's esophagus (BE) represents a pre-cancerous condition that is characterized by the metaplastic conversion of the squamous esophageal epithelium to a columnar intestinal-like phenotype. BE is the consequence of chronic reflux disease and has a potential progression burden to esophageal adenocarcinoma (EAC). The pathogenesis of BE and EAC has been extensively studied but not completely understood, and it is based on two main hypotheses: "transdifferentiation" and "transcommitment". Omics technologies, thanks to the potentiality of managing huge amounts of genetic and epigenetic data, sequencing the whole genome, have revolutionized the understanding of BE carcinogenesis, paving the way for biomarker development helpful in early diagnosis and risk progression assessment. Genomics and transcriptomics studies, implemented with the most advanced bioinformatics technologies, have brought to light many new risk loci and genomic alterations connected to BE and its progression to EAC, further exploring the complex pathogenesis of the disease. Early mutations of the TP53 gene, together with late aberrations of other oncosuppressor genes (SMAD4 or CKND2A), represent a genetic driving force behind BE. Genomic instability, nonetheless, is the central core of the disease. The implementation of transcriptomic and proteomic analysis, even at the single-cell level, has widened the horizons, complementing the genomic alterations with their transcriptional and translational bond. Increasing interest has been gathered around small circulating genetic traces (circulating-free DNA and micro-RNAs) with a potential role as blood biomarkers. Epigenetic alterations (such as hyper or hypo-methylation) play a meaningful role in esophageal carcinogenesis as well as the study of the tumor micro-environment, which has led to the development of novel immunological therapeutic options. Finally, the esophageal microbiome could be the protagonist to be investigated, deepening our understanding of the subtle association between the host microbiota and tumor development.

Indexed as

Barrett esophagusepigenomicsesophageal cancergenomicsmetaplasiamiRNAsomicstranscriptomics

Identifiers

PMID39950103
PMCPMC11821489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.